Analyst Ratings for Bright Minds Biosciences Inc. (DRUG)

DRUG Rating Summary

DRUG Price Target Summary

* Over Last 12-Mos
  |   Expand Research on DRUG
Overall Rating: BUY   Rating Trend: Up   Avg. $ Target: $156.60 (+110.4%) * Over Last 12-Mos
Rating Score: 10 / 10   Percentile Rank: 95%
Date Firm Analyst Type Rating
(Past)
PT
(Past)
Start $
(End $)
% Chg. Details
4/13/2026 Jefferies Andrew Tsai New Coverage Buy
(N/A)
145.00
(N/A)
85.91
(74.42)
-13.37% Details
9/8/2025 BTIG
» Updated 3/30/2026
Thomas Shrader New Coverage Buy
(N/A)
147.00
(N/A)
42.24
(74.42)
76.18% Details